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Abstract
Purpose: The goal was to identify molecular imaging probes that would enter the brain, selectively
bind to Parkinson’s disease (PD) pathology, and be detectable with one or more imaging modalities.
Procedure: A library of organic compounds was screened for the ability to bind hallmark
pathology in human Parkinson’s and Alzheimer’s disease tissue, alpha-synuclein oligomers and
inclusions in two cell culture models, and alpha-synuclein aggregates in cortical neurons of a
transgenic mouse model. Finally, compounds were tested for blood–brain barrier permeability
using intravital microscopy.
Results: Several lead compounds were identified that bound the human PD pathology, and some
showed selectivity over Alzheimer’s pathology. The cell culture models and transgenic mouse
models that exhibit alpha-synuclein aggregation did not prove predictive for ligand binding. The
compounds had favorable physicochemical properties, and several were brain permeable.
Conclusions: Future experiments will focus on more extensive evaluation of the lead compounds
as PET ligands for clinical imaging of PD pathology.
Key words: Parkinson’s disease, Dementia with Lewy bodies, Lewy bodies, Lewy Neurites,
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Introduction
Parkinson’s disease (PD) is the second most commonneurodegenerative disorder. The prevalence of PD is
estimated at 1 % of people over 60 years of age and 0.3 % of
the entire population. Despite the discovery of PD nearly
200 years ago, a clinical diagnosis is still the prevailing
method to assess the disease [1]. PD is pathologically
characterized by abnormal deposition of alpha-synuclein in
multiple brain regions, speciﬁcally in the substantia nigra
pars compacta in Lewy bodies (LB) and Lewy neurites
(LN). These pathological features are thought to be upstream
of several debilitating clinical symptoms, such as progres-
sive bradykinesia, rigidity, and often a rest tremor [2].
Traditional CT and MRI imaging cannot detect PD
pathology in the brain [2]. To date, there is no intrinsic
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contrast of alpha-synuclein or Lewy pathology that can be
exploited for noninvasive imaging. Currently, radioligands
are being used clinically to monitor the activity of the
dopamine transporter (DaTSCAN) [3–5]. In PD, levels of
dopamine in certain regions have been shown to be
signiﬁcantly reduced [6]. While these imaging agents may
be of some beneﬁt in monitoring or diagnosing PD, they are
an indirect measure of the disease. A single-photon-emission
PET imaging probe would be particularly useful for
population-based epidemiological research, permitting early
detection and therapeutic monitoring. Despite the develop-
ment of exogenous biomarkers for other neurodegenerative
diseases, there are no probes for the pathology of PD. An
imaging biomarker of alpha-synuclein or Lewy pathology
for PD would aid in allowing physicians to distinguish PD
from other neurodegenerative diseases.
In the past decade, signiﬁcant progress has been made in
developing imaging biomarkers using positron emission
tomography (PET) radiotracers for intracranial pathology.
Pittsburgh Compound B (PiB) has been developed and
evaluated for use in Alzheimer’s disease (AD). The
radiotracer labels amyloid pathology in animal models [7, 8]
and in humans [9]. Recently, ﬂorbetapir has been approved for
clinical amyloid imaging and shares physicochemical proper-
ties with PiB. Both reagents bind speciﬁcally to ﬁbrillar beta-
amyloid found in compact and cored plaques, a pathology that
is present in several neurodegenerative diseases and the
hallmark of AD [10].
The identiﬁcation of an imaging agent speciﬁc to Lewy
pathology, would greatly advance research for PD. The goal
of this study was to identify an imaging probe for PD,
analogous to PiB for AD. The main criteria for a successful
imaging biomarker include: high afﬁnity binding to Lewy
body and Lewy neurite pathology; speciﬁcity to alpha-
synuclein pathology over amyloid pathology, ability to
traverse the blood–brain barrier (BBB) to access neuronal
tissue, quick clearance of the compound not bound to Lewy
pathology and the absence of radiolabeled metabolites in the
brain [11]. Based on previous work screening AD-related
imaging probes, a library of compounds was compiled that
was selected based on good physicochemical properties for
brain entry. The probes in this library, either novel or
commercially available, are low molecular weight, un-
charged, ﬂuorescent, and rational candidates for BBB
penetration and noninvasive imaging. These small molecule
compounds were untested in their ability to bind PD
pathology.
Several screening methods were used, both in vitro and in
vivo, to characterize the compounds in our library with the
goal of identifying suitable candidates for imaging ligands.
The ﬁrst screening method evaluated the ability to bind
Lewy pathology in ﬁxed human midbrain tissue from
neuropathologically diagnosed DLB cases. This was consid-
ered the gold standard. In addition, two cell culture models
were utilized, which overexpress alpha-synuclein and devel-
op soluble oligomers or insoluble aggregates, with the
intention of developing a high-throughput screen to identify
compounds that bind to the aggregated alpha-synuclein
protein. Additionally, the ability of the compounds to label
alpha-synuclein in the brain tissue of a transgenic mouse
model, which overexpresses human alpha-synuclein in a
subset of neurons, was evaluated. Finally, intravital micros-
copy tools were used to characterize the BBB penetration of
the leading compounds in the intact mouse. Several lead
compounds were identiﬁed which showed speciﬁcity for
Lewy pathology, were able to cross the BBB, and will be
evaluated further as suitable candidate PET ligands for
clinical imaging in PD.
Materials and Methods
Materials
A library of over 100 ﬂuorescent compounds that were either novel
compounds or obtained from commercial sources was screened.
LDS-722, LDS-759, LDS-798, LDS-730, Nile Blue 690 Cl04,
HITC Cl04, and Stilbene 420 were purchased from Exciton
(Dayton, OH). THK-265 was obtained from Organica (Wolfen,
Germany). 3-3´-Diethylthiadicarbocyanine iodide (33´DTDCI) was
purchased from Sigma (St. Louis, MO). Nile red was purchased
from Life Technologies (Invitrogen, Grand Island, NY). Novel
imaging probes, RD-1 and NIAD-1, were synthesized by Dr.
William Klunk at the University of Pittsburgh School of Medicine
and Dr. Timothy Swager at Massachusetts Institute of Technology,
respectively. Compounds were solubilized and stored as stock
solutions in 100 % DMSO. Working solutions of each compound
were diluted from stock with phosphate-buffered saline (PBS) to
500 nM, 2 μM, and 5 μM. General lab chemicals and cell culture
supplies were purchased from Life Technologies (Invitrogen,
Grand Island, NY). Synuclein monoclonal antibody H3C was a
gift from Julia George (University of Illinois) and monoclonal anti-
synuclein antibody was obtained from BD Biosciences (San Jose,
CA). Alexa Fluor 488 secondary antibody was obtained from Jackson
ImmunoResearch (West Grove, PA), and Cy5 ﬂuorescent-conjugated
secondary antibody from Invitrogen (Grand Island, NY).
Animal Models
C57Bl/6J wildtype mice were obtained from Jackson Laboratory
(Bar Harbor, ME, USA). Human recombinant synuclein-eGFP
transgenic mice (Synuclein-GFP) were a gift from Eliezer Masliah
(University of California San Diego). All experiments were
conducted with approval of the Massachusetts General Hospital
Animal Care and Use Committee and in compliance with NIH
guidelines for the use of experimental animals.
Human Tissue Collection
Postmortem midbrain tissue from DLB (Dementia with Lewy
Bodies) and PD patients was obtained from the Harvard Brain
Tissue Resource Center at McLean Hospital. Parafﬁn-embedded
formalin-ﬁxed tissue from the temporal lobe of AD patients was
obtained through the Massachusetts Alzheimer's Disease Research
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Center Brain Bank. The human brain tissue provided was
neuropathologically deﬁned as DLB tissue using standard criteria
[12, 13].
LogP Estimates for Imaging Agents
LogP was measured for the lead compounds using reverse phase
C18 high-performance liquid chromatography (HPLC) as previously
described [14]. Brieﬂy, the retention time on an HPLC system
(Phenomenex Prodigy ODS-3) with UV detection at 365 nm was
measured using a ﬂuorescence detector and the speciﬁc excitation and
emissions peaks for each compound.
Labeling of Synuclein Pathology in Human DLB
and PD Cases
Blocks of midbrain tissue from human PD/DLB cases were ﬁxed
with 4 % paraformaldehyde and stored at −80 °C. In preparation for
immunohistochemistry, the tissue block was deparafﬁnized with
xylene and rehydrated. Midbrain tissue was sliced into 40-μm thick
sections with a freezing sledge Leica SM 2000R microtome. Free-
ﬂoating tissue was permeabilized with 0.5 % Triton-X 100, then
incubated with normal goat serum (NGS) at room temperature for
1 h with shaking. Primary H3C antibody (1:5,000 in 1.5 % NGS) to
alpha-synuclein [15] was incubated overnight at 4 °C with shaking,
and then washed with 1X PBS three times. The tissue was then
incubated for 2 h at room temperature with a ﬂuorescent secondary
antibody labeled with Alexa Fluor 488 or Cy5 (1:200 in PBS).
Tissue was then treated with the compound to be tested. Each slice
was incubated at room temperature for 30 min with either 500 nM,
2 μM, or 5 μM of compound dissolved in PBS. The tissue was
rinsed with three washes of PBS, and then mounted onto Adhesion
Superfrost Plus slide and cover slipped. The tissue was imaged with
an Olympus upright microscope (BX51, Melville, NY) using
appropriate excitation/emission ﬁlters for Alexa Fluor 488, Cy5,
or a white light broadband ﬁlter to detect both anti-synuclein and
the screened compounds simultaneously.
Cell Culture Models with Intracellular
Alpha-Synuclein Inclusions
Syn-T/Syn-1 model: H4 cells were maintained in culture, split to a
four-chamber slide (Lab-Tek) and transfected using SuperFect
Transfection Reagent (Qiagen) with DNA for synuclein-T and
synphilin-1 to promote synuclein inclusion formation, as previously
described [16]. Synphilin-1 is an alpha-synuclein interacting
protein that co-localizes with the carboxy-terminal-truncated al-
pha-synuclein protein in separate cytoplasmic inclusions [17].
Transfected cells were kept in an incubator overnight to allow
sufﬁcient protein expression. The cells were then ﬁxed with 4 %
paraformaldehyde and treated with 1.5 % NGS/0.1 % Triton-X in
PBS for 45 min at room temperature. Cells were immunostained
with an anti-synuclein primary antibody (H3C, 1:1,000) in 1.5 %
NGS in PBS for 2 h with shaking. Cells were washed with PBS,
then incubated with ﬂuorescent secondary antibody, either Alexa
Fluor 488 or Cy5 (1:200 in PBS) for 1 h. Cells were washed with
and stored in PBS at 4 °C. Transfected cells were stained with
5 μM of the test compound in PBS for 30 min, washed in PBS, and
imaged with an Olympus BX51 upright microscope with a ×60,
NA01.2 objective (Olympus Plan Neoﬂuar, Thornwood, NY).
Alpha-Synuclein Fluorescence Complementation
Cell Model
H4 cells were maintained in culture, split to a four-chamber slide (Lab-
Tek), and were co-transfected with DNA for an alpha-synuclein-
dependent ﬂuorescent protein complementation assay as previously
described [18, 19]. The N-terminus half of VenusYFP fused to alpha-
synuclein and a separate construct with the C-terminus half of
VenusYFP fused to alpha-synuclein protein were co-transfected with
SuperFect Transfection Reagent (Qiagen). When two or more alpha-
synuclein proteins interact, the VenusYFP ﬂuorescence is
reconstituted from the non-ﬂuorescent halves, and can be used as a
marker for alpha-synuclein oligomerization. The appearance of
ﬂuorescence demonstrates at a minimum the formation of dimers of
alpha-synuclein; however, higher molecular weight oligomers are also
formed [18]. After ﬁxation with 4 % paraformaldehyde in PBS, cells
were incubated with 5 μM of ﬂuorescent ligand for 30 min in PBS at
room temperature. Slides were rinsed with PBS three times and then
imaged using an Olympus BX51 microscope with a ×60, NA01.2
objective (Olympus Plan Neoﬂuar, Thornwood, NY).
Binding in Alpha-Synuclein–GFP Mouse Model
Formalin-ﬁxed 40-μm sections from synuclein–eGFP mice ex-
pressing human alpha-synuclein fused to GFP under the platelet-
derived growth factor beta (PDGF-b) promoter were used to
evaluate the labeling of alpha-synuclein in a mouse model. In this
mouse model, synuclein–GFP is expressed in a subset of cortical
neurons and accumulates at pre-synaptic terminals [20, 21]. The
free-ﬂoating tissue was incubated with 500 nM or 5 μM of the
imaging agent in PBS. Tissue sections were washed with PBS,
mounted on a slide, and imaged using a Leica LCM confocal
microscope at ×63 (Plan Apo, NA01.2, Leica) with 488, 543, or
633 nm laser excitation and appropriate emission ﬁlters.
Speciﬁcity Over AD Pathology
Parafﬁn-embedded paraformaldehyde (4 %)-ﬁxed sections of the
temporal lobe of neuropathologically veriﬁed human AD tissue
were deparafﬁnized. Tissue sections were stained with 0.05 %
thioﬂavin S (Sigma, St. Louis, MO) in 50 % ethanol for 5 min to
visualize senile plaques and neuroﬁbrillary tangles (NFT). The
tissue was then incubated with 5 μM of compound in PBS for
20 min at room temperature. Slides were rinsed in PBS,
coverslipped, and then imaged on an Olympus BX51 microscope
using a ×20 Plan Neoﬂuar objective (NA00.7, Olympus,
Thornwood, NY), with a GFP emission ﬁlter for thioﬂavin S and
appropriate emission ranges for each compound.
In Vivo Imaging for BBB Permeability
Craniotomies in C57Bl/6J wildtype mice, 3–4 months old, were
performed as previously described with minor modiﬁcations [22].
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In brief, animals were anesthetized using 2 % isoﬂurane in balanced
oxygen, and then a 5-mm diameter skull ﬂap was removed. A
craniotomy was performed, and the exposed brain area was covered
by an 8-mm round glass coverslip, which was sealed to the skull
with dental cement [22, 23]. This procedure allowed a transparent
window into the mouse brain for use with in vivo microscopy of the
cerebrovasculature. The mice were allowed 2–3 weeks for complete
recovery after the craniotomy prior to imaging.
For imaging, the mice were anesthetized with 2 % isoﬂurane in
balanced oxygen and secured in a custom stereotaxic frame, which
ﬁt into the microscope stage. Each imaging compound was
solubilized in 1–6 % DMSO, 15 % Cremophor EL, and 1X PBS,
and injected at a ﬁnal concentration of 2–10 mg/kg. All in vivo
imaging was performed using a custom-built epiﬂuorescent
microscope with a cooled CCD camera (Hamamatsu, ORCA-ER,
C4742-80, Japan), objective (XFluor 2×/340, NA 0.14, Olympus,
Japan), and appropriate excitation and emission ﬁlters for the
compounds. Pre-injection images were taken, and then the solution
of compound was injected IV (200–300 μL) into the tail vein of the
anesthetized mouse. A time course during and after the injection
was taken for up to 60 min post-injection. The camera was controlled
and images were acquired using Micro-Manager software [24] and
analyzed using ImageJ [25].
Results
Speciﬁcity of Compounds for PD Pathology
in Human Tissue
To determine whether compounds exhibited speciﬁcity for
alpha-synuclein pathology, the binding characteristics of the
various imaging probes were tested by incubating the
compounds with human DLB or PD tissue. Alpha-synuclein
pathology was detected using immunohistochemistry with
an anti-synuclein antibody. Tissue was washed with PBS
and then imaged using appropriate optical parameters. The
compounds showed variable binding patterns to Lewy
bodies and Lewy neurites. The imaging agents that bound
Lewy bodies (+), but did not bind Lewy neurites (−),
included 33´DTDCI, LDS-759, LDS-798, NIAD-1, Nile red,
RD-01, THK-265, LDS-730, Nile blue, and HITC. Two
probes, LDS-722 and Stilbene, showed speciﬁc staining of
both LB and LN pathology, with a low amount of
nonspeciﬁc background ﬂuorescence (Fig. 1a). These results
are summarized in Table 1. The majority of compounds
screened did not show any speciﬁcity to alpha-synuclein
pathology above nonspeciﬁc tissue ﬂuorescence (Fig. 1b).
The screened compounds that did not bind PD pathology are
not reported in this study. Representative images are
depicted in Fig. 1a, b.
Labeling of Cell Culture Models of Alpha-Synuclein
Accumulation
The utility of two cell culture models of alpha-synuclein
aggregation were evaluated for the purpose of developing
a high-throughput screening assay for potential imaging
agents. The ﬁrst cell model forms alpha-synuclein in-
clusions when synuclein (Syn-T) and synphilin-1 are co-
expressed [16]. H4 cells expressing Syn-T and Syn-1
were immunostained for alpha-synuclein and then incu-
bated with the imaging probe. Cells were washed with
PBS and imaged under appropriate optical conditions.
Several compounds demonstrated labeling of H4-SynT/
Syn-1 cells without any speciﬁcity for the synuclein
oligomers. Other compounds did not show binding to
Fig. 1. Labeling of Lewy bodies (LB) and Lewy neurites (LN) in DLB postmortem midbrain tissue. a Shows positive staining (+) of
Parkinson’s disease (PD) pathology with compound LDS-722 (2 μM). b Shows negative staining (−) of pathology with compound
Oxazine 750 (5 μM). The first image in each panel shows labeling of alpha-synuclein pathology with the H3C antibody and the
secondary Alexa Fluor 488 (green). The circular LB is to the right in each image and LNs are to the left in the image. The second image
shows the binding of the screened compound to the DLB tissue (red). The third image shows the two channels merged. A
combination of a yellow–orange color indicates co-localization of alpha-synuclein with IHC and the screened compound.
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Table 1. Summary of the screening results for lead compounds
Compound 
Compound Structure  
MW 
(Da) 
EX 
(nm) 
EM 
(nm) LogP 
PD 
LB 
PD 
LN 
Syn-
GFP 
Mice 
AD 
Plaq 
AD 
NFT 
BBB 
Cross 
33’DTDCI 573 656 673 2.31 + - - + - - 
LDS-722 379 495 702 1.04 + + - + + + 
+--+-+88.2637855515*957-SDL
LDS-798* 429 558 766 1.80 + - - - - + 
NIAD-1 
H O
NS
S
+
S O 2O
- 550 540 720 1.52 + - - + + + 
Nile Red* 318 552 620 3.51 + - + - - + 
+-+--+93.151600631410-DR
THK-265 350 640 663 <1 + - - + - - 
LDS-730 430 603 668 1.54 + - - + + + 
Nile Blue* 417 624 660 1.41 + - + - - + 
HITC* 509 751 790 2.75 + - - - - + 
Stilbene 562 350 425 1.25 + + n/a + + + 
X  = h ete ro ato m
R  = a lkyl gro up
S truc ture  w ith rigidized  ring
N
+
X
R
N
R
R
S
N
OH
N
N
OH
OH
The ﬁrst ﬁve columns identify several characteristics of each compound. The next ﬁve columns outline positive (+) and negative (−) binding to pathology in
Parkinson’s midbrain tissue and Alzheimer’s temporal lobe tissue, and labeling of alpha-synuclein mouse models. The last column identiﬁes compounds that
crossed the BBB in vivo in wild-type mice (n = 3 per compound). MW molecular weight in daltons, EX max excitation wavelength in nanometers, EM max
emission wavelength in nanometers, LogP octanol/water partition coefﬁcient to indicate lipophilicity, PD LB Lewy bodies in DLB tissue, PD LN Lewy
neurites in DLB tissue, AD Plaq senile plaque labeling in AD tissue, AD NFT neuroﬁbrillary tangle labeling in AD tissue, BBB cross ability to penetrate the
blood brain barrier in vivo
*Lead compounds with alpha-synuclein speciﬁcity
n/a Not evaluated in the assay
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either the cells or the inclusions. Representative images
are shown in Fig. 2.
The second cell culture model uses a protein comple-
mentation assay to detect alpha-synuclein oligomers in cells.
H4 cells co-expressed alpha-synuclein fused to N-terminal-
VenusYFP and alpha-synuclein fused to C-terminal–
VenusYFP. The YFP ﬂuorescence is reconstituted when
two or more alpha-synuclein proteins interact [18, 19]. Cells
were incubated with imaging probes, washed with PBS, and
imaged under appropriate conditions, as described above.
Similar results were obtained with this cell culture model;
there was no speciﬁc labeling of the alpha-synuclein
Synuclein- IHC LDS 759 Merged
Synuclein-IHC THK-265 Merged
a
b 
Fig. 2. Compounds are not specific to alpha-synuclein-T/synphilin-1 intracellular inclusions or alpha-synuclein-expressing H4
cells. a Shows LDS-759 (5 μM) as a representative positive labeling of all cells. b Shows THK-265 (5 μM) as a representative
compound that did not label any cells. None of the compounds bound to alpha-synuclein–synphilin intracellular inclusions. The
first image shows fluorescence of alpha-synuclein with H3C antibody in transfected cells (green). The second image (red)
shows fluorescence of the imaging probe. The third image shows the two channels merged. There is no overlap of probe and
alpha-synuclein IHC on inclusions or specific to alpha-synuclein-transfected cells.
MergedSynuclein IHC
Synuclein IHC
THK-265
LDS 759 Mergeda
b
Fig. 3. The compounds did not specifically label VenusYFP–synuclein-transfected H4 cells. a Illustrates a representative
image of compound, LDS-759 (5 μM), which labeled all cells, transfected and non-transfected. b Shows THK-265 (5 μM), a
probe that did not label any cells. The first image shows alpha-synuclein YFP fluorescence (green) in cells, the second image
shows probe fluorescence (red), the third image shows the two channels merged (yellow indicates co-localization). None of the
compounds bound specifically to only the transfected cells, indicating that the compounds were not specific to the alpha-
synuclein species expressed in the cells.
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oligomers in the Syn-YFP cells with compounds that bound
to the Lewy bodies in human tissue. Representative images
are shown in Fig. 3. These cell culture models of alpha-
synuclein accumulation did not predict binding to
neuropathologically identiﬁed Lewy bodies found in the
human brain. These results may be due to the non-ﬁbrillar
nature of alpha-synuclein oligomers in these cell culture
models.
Syn-GFP
Syn-GFP
Nile Blue 690
  3-3’-DTDCI
Merged
Merged
a
b
Fig. 4. Compounds are not specific to the alpha-synuclein aggregates in synuclein–GFP expressing neurons of transgenic
mouse cortical tissue. Syn-GFP is present at the synaptic terminals, shown as punctate fluorescence in the images and
expressed in the soma of about 1 % of cortical neuron [20, 21]. a Illustrates a representative image of nonspecific labeling of
mouse cortical tissue by Nile blue 690 (500 nM). Probe 3-3´DTDCI (500 nM) demonstrates a representative image of negative
labeling or the absence of fluorescence in transgenic mouse cortical tissue. b The first images in both panels show the
distribution of synuclein–GFP in the cortex of the transgenic mouse brain. The second image shows the fluorescence (red) of
the screened compound on the same cortical tissue. These images show that there is no specific labeling of either compound
to the alpha-synuclein expressed in the Syn-GFP transgenic mouse model.
Thio-Sa
b
Merged
Thio-S LDS 798 Merged
NIAD-1
Fig. 5. The candidate imaging agents showed varied labeling patterns of senile plaques and neurofibrillary tangles in
Alzheimer’s disease temporal lobe tissue. a Demonstrates that compounds that bound to Lewy Bodies like NIAD-1 (5 μM) also
bound to amyloid plaques and tau neurofibrillary tangles. b Shows LDS-798 (5 μM), which did not bind to either plaques or
tangles in AD. The first image in each panel is AD tissue labeled with 0.05 % thioflavin S (Thio-S). The second image shows the
fluorescence (red) of the screened compound on the tissue. The final image in each panel is a merged view of Thio-S and the
compound on AD pathology. A combination of a yellow-orange color indicates co-localization of Thio-S and the compound, as
seen with NIAD-1 on plaques and tangles in panel a.
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Labeling of Alpha-Synuclein Pathology
in a Mouse Model
The utility of an alpha-synuclein mouse model as an
additional screening tool for in vivo analysis of imaging
probes was evaluated. In the Syn-GFP mouse model, an
alpha-synuclein–GFP fusion protein, under a PDGF promot-
er, is expressed in 1 % of cortical neurons and shows
localization at pre-synaptic terminals [20, 21]. To determine
if any of the compounds demonstrated binding to Syn-GFP
neurons, 40-μm sections of tissue were incubated with the
imaging probes. The tissue was washed with PBS and
optical imaging was performed under appropriate conditions.
None of the compounds showed selective binding to the
Syn-GFP expressing neurons or alpha-synuclein localized at
synapses. Some compounds bound non-speciﬁcally to
cellular membranes, while others showed no evidence of
binding. Representative images are shown in Fig. 4.
Selectivity over Alzheimer’s Pathology in Human
AD Tissue
To determine the speciﬁcity of our compounds for alpha-
synuclein pathology, lead candidates were screened for
binding to senile plaques and NFT, the main pathological
hallmarks of Alzheimer’s disease. Human AD tissue was
stained with 0.05 % thioﬂavin S and then incubated the
imaging probes individually on the tissue. The compounds
showed various binding patterns to AD pathology. A few
compounds had positive staining and bound both amyloid-
beta plaques and NFT. Several imaging agents bound to
plaques but not tangles. A few compounds did not bind
either pathology. These results are summarized in Table 1.
Probes LDS-759, LDS-798, Nile blue, HITC, and Nile red
did not label amyloid or tau pathology in the human AD
tissue. This suggests that these ﬁve compounds show some
selectivity for Lewy pathology in human tissue. Represen-
tative images are shown in Fig. 5a, b.
BBB Permeability of Screened Compounds
Compounds that bound to PD pathology were further
assessed for BBB permeability with intravital microscopy.
Anesthetized mice (n03 per compound) were administered
compounds via IV injection through a tail vein at 2–10 mg/
kg of ligand. Optical imaging was performed to monitor the
ﬂuorescent molecule in the cerebrovasculature. A time
course after an IV injection of each compound was obtained.
An agent that crossed the BBB was ﬁrst ﬂuorescent in the
cerebrovasculature and then showed progressive leakage
from the vasculature into the parenchyma. Agents that did
not exhibit BBB penetration remained ﬂuorescent in the
vasculature over time and did not appear to change location.
Several of the compounds tested including, LDS-722, Nile
Fig. 6. Real-time imaging in wildtype mice, showing blood–brain barrier permeability time courses for representative
compounds after intravenous tail vein injection. The first image in each panel shows the brain prior to injection of the
compound. The subsequent images are selected points from the time series. a Illustrates a time course of LDS-798 (4 mg/kg)
crossing the blood–brain barrier into the parenchyma and clearing from the cerebrovasculature within 4 min. b A time course of
THK-265 (4 mg/kg) appearing in the cerebrovasculature; subsequent images demonstrate that it does not detectably cross into
the brain parenchyma within 5 min. THK-265 shows a steady signal in the vasculature throughout the time series, up to 60 min
(not shown).
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blue, and LDS-798, showed BBB permeability. More-
over, the majority of compounds that crossed the BBB
also cleared from the cerebrovasculature within 10 min.
Ligands that did not traverse the BBB remained ﬂuorescent
in the vasculature for an extended period of time and
were imaged for up to 1 h. These data are also included
in Table 1. Representative time series images are shown
in Fig. 6.
Discussion
PD is a progressive neurodegenerative disease that would
beneﬁt from noninvasive biomarkers for alpha-synuclein
pathology, which would permit early diagnosis and
provide a quantitative endpoint for clinical trials. Molecular
imaging in AD has beneﬁted from advances in probe design
leading to PET imaging of amyloid deposits in AD patients.
PiB and ﬂorbetapir have permitted longitudinal imaging of the
natural progression of amyloid deposition and are currently
being used as an outcome measure in clinical trials of
therapeutic agents [26]. This success has encouraged the
development of molecular imaging agents targeting the
pathological aggregates of alpha-synuclein found in PD.
PD is characterized by the presence of LB and LN.
Currently, little is known about how or why these distinctive
aggregates form. It has been established that small diffusible
oligomers of alpha-synuclein play a role in cytotoxicity, and
evidence suggests that the larger alpha-synuclein aggregates
may even be neuroprotective [18]. Thus, while LB and LN
are the most obvious target as an imaging biomarker, it has
yet to be established if they will be the most relevant or
informative target. The most useful imaging probe would
probably be one that reports both Lewy aggregates and
smaller diffusible oligomers. This approach would increase
sensitivity by detecting a broader range of targets.
A small library of compounds was screened as putative
molecular imaging ligands for Lewy pathology. The com-
pounds have desirable physicochemical properties permit-
ting reasonable solubility, and the potential to cross the
blood–brain barrier when administered systemically. Using
real-time intravital microscopy, it was determined that some
of these compounds could enter the brain with promising
kinetics. Thus, it was determined that it is possible to
identify molecular imaging agents that could be suitable for
testing in humans.
Despite the recent success of amyloid targeting PET
agents, the development of CNS targeting probes is
extremely difﬁcult. The blood–brain barrier is a major
obstacle and limits the size of the small molecule agent to
G600 MW. Likewise, lipophilicity is a major determinant of
passive blood–brain barrier entry. The lipophilicity of
successful small molecule imaging agents, as deﬁned by
logP (octanol–water partition index), is limited to a range
between ~1 and 3 [27]. Our lead compounds were of low
molecular weight and had logP values that mostly fell within
this range.
The results from the cell culture and animal models of alpha-
synuclein overexpression were surprising. The intent of the cell
culture experiments was to enable a higher throughput approach
to screening ﬂuorescent ligands; however, none of the com-
pounds that bound to alpha-synuclein pathology in the human
brain tissue sections bound to the oligomers or inclusions in the
cell culture models. Thus, the cell-based models were not
predictive of binding patterns to bona ﬁde Parkinson’s disease
pathology. This suggests that solely overexpressing the alpha-
synuclein protein in cells for a few days does not accurately
model the complex 3D structure of alpha-synuclein containing
LBs, which likely takes years to form.
The same lack of speciﬁc binding was observed in the
transgenic mouse model overexpressing alpha-synuclein,
despite the presence of high molecular weight species and
continuous expression of the human protein over the animal’s
life span. This result was conﬁrmed in tissue from virally
induced alpha-synuclein expression in rats (data not shown).
One possible explanation for the lack of detectable binding in
the cell culture models, transgenic mouse model, and virally-
induced rat model is a low-afﬁnity binding of the ligands
combined with an assay that lacks sensitivity compared with
other approaches. The simplest explanation for the lack of
binding in these synuclein expressing models is that they lack
ﬁbrillar forms of the protein aggregates, which would more
closely resemble the conformation found in Lewy bodies.
Together, these data suggest that there is much to learn about
alpha-synuclein aggregation, and that the ﬁeld would substan-
tially beneﬁt from amore relevant cell and animal model of PD.
Finally, we believe that speciﬁcity for Lewy bodies and Lewy
neurites, and not just alpha-synuclein aggregates, is the relevant
target for clinical imaging in PD patients.
A major confound for speciﬁc detection of LB pathology
is the common coexistence of amyloid aggregates in PD
patients. Amyloid plaques are large extracellular deposits
that can occupy up to several percent of local brain volume.
Therefore, it will be critical to have an imaging ligand that
displays selectivity over amyloid pathology. Since there are
no crystal structures yet to allow rational design of ligands
for either LB or senile plaques, our library was screened for
binding to amyloid plaques in human tissue from AD cases.
Most amyloid binding reagents are not speciﬁc for amyloid-
beta aggregates but prefer the beta-sheet structure of protein
aggregates common to both alpha-synuclein and amyloid.
Despite this, several compounds were identiﬁed that showed
speciﬁcity for LB over amyloid plaques. This result suggests
that it is possible to identify a probe that will not “cross
react” with Alzheimer pathology.
Our ﬂuorescence-based assays and intravital microscopy
tools allowed us to characterize the pharmacokinetics of our
lead compounds in the mouse brain. While largely qualita-
tive, this approach allowed us to monitor the appearance of
the compound in the cerebrovasculature during IV injection,
and watch in real time as the compound crossed or did not
cross the blood–brain barrier. Similarly, the images allowed
us to follow the clearance of compound from both the brain
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parenchyma and the circulation over time. An ideal PET
ligand would enter the brain in sufﬁcient amounts and then
be cleared from the brain and circulation very quickly to
allow speciﬁc detection of probe that is bound to target.
Because our compounds do not bind to oligomers in the
animal model of alpha-synuclein expression, we were not
able to observe brain entry and alpha-synuclein staining in
vivo. Nonetheless, our in vivo imaging results demonstrate
that it is possible to identify a compound that binds to PD
pathology and has the physicochemical properties consistent
with brain penetration.
A key property of any imaging ligand is afﬁnity for the
target. While the afﬁnities of the compounds for LB
pathology in ﬁxed human tissue sections was not measured,
the optical contrast was qualitatively rated as an estimate of
the degree of binding. Additionally, as formalin-ﬁxed tissue
was used to increase throughput in the screening approach, it
is possible that fresh frozen tissue sections would have led to
different binding properties and potentially led to more
suitable reagents. Regardless, it will be important to evaluate
the suitability of the putative imaging agents in humans.
It would be desirable to develop a predictive model of
alpha-synuclein aggregation that is compatible with standard
competitive binding techniques to quantitatively determine
the afﬁnity of our compounds. While numerous approaches
for using recombinant alpha-synuclein aggregates have been
described, it is not clear that any of these formulations will
represent the binding observed to LB in human tissue.
Likewise, a competitive binding assay requires a gold
standard compound to compete with, and to date that would
be either Thioﬂavin T or Thioﬂavin S. Both of these
compounds bind with very low contrast to LB pathology
and thus are probably very low afﬁnity binders. Therefore,
one of the outcomes of this current work is the demonstra-
tion of putative alpha-synuclein binding compounds that
could become a benchmark for evaluating alpha-synuclein
aggregate formulations as well as ﬁrst generation tools
towards identifying high-afﬁnity binding sites.
In summary, using ﬂuorescence-based screening of a
small library of ﬂuorescent compounds several lead com-
pounds were identiﬁed as candidates for molecular imaging
of LB pathology in PD patients. These compounds show
speciﬁcity for alpha-synuclein pathology over amyloid
pathology in human tissue sections, have low molecular
weights, logP values that are consistent with good brain
entry, and do, in fact, cross the blood–brain barrier. Thus,
these compounds represent proof in concept that a PD
molecular imaging agent can be developed and should at
least serve as starting points for optimized probe develop-
ment. For clinical imaging using PET, these compounds will
need to be radiolabeled and their biodistribution and
pharmacokinetics evaluated more rigorously. It will also be
important to evaluate these compounds for toxicity. Ulti-
mately, these contrast agents or similar compounds hold the
potential to monitor Parkinson's disease pathology longitu-
dinally and allow correlation of these changes with the onset
and progression of symptoms. Additionally, a successful
compound would provide an ideal quantitative end point for
analyzing therapeutics aimed at eliminating the main
pathological aggregates of PD.
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